Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane

NCT07673029 is registered in ClinicalTrials.gov with GeneQuantum Healthcare (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07673029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07673029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
January 10, 2025
Completion date
January 9, 2028
Enrollment
228 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer